Isofol Medical AB (SE:ISOFOL)
:ISOFOL
Want to see SE:ISOFOL full AI Analyst Report?
ISOFOL Stock Chart & Stats
kr0.72
-kr0.10(-6.34%)
At close: 4:00 PM EST
kr0.72
-kr0.10(-6.34%)
Day’s Range― - ―
52-Week Rangekr0.55 - kr1.53
Previous CloseN/A
Volume134.77K
Average Volume (3M)501.89K
Market Cap
kr229.79M
Enterprise Valuekr177.26M
Total Cash (Recent Filing)kr126.99M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta0.70
Next Earnings
Aug 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.27
Shares Outstanding320,491,640
10 Day Avg. Volume847,726
30 Day Avg. Volume501,890
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)1.46
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.19
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / No DebtZero reported debt across 2023–2025 materially reduces financial risk and interest burden, giving management greater optionality. For a pre-commercial biotech this durable capital structure lowers default risk and lengthens runway versus peers with leverage, aiding long-term R&D continuity.
Improving Cash Burn TrendSustained reduction in operating cash outflows signals better cost discipline and more efficient R&D spending. This structural improvement increases the company’s effective runway and reduces near-term financing needs, improving the odds that trials progress without immediate dilutive funding.
Focused Oncology R&D Business ModelA concentrated R&D focus on adjunct cancer therapies aligns with persistent, structural unmet medical needs and large addressable markets. Specialization can create scientific expertise, clearer regulatory pathways and potential for partnership/licensing deals, supporting durable strategic optionality.
Bears Say
No Current RevenueAbsence of recurring revenue is a fundamental constraint: it prevents internal funding of development, lengthens time to self-sufficiency, and forces reliance on external capital. Over a multi-month horizon this structural gap limits strategic flexibility and increases dilution or financing risk.
Persistent And Rising Net LossesConsistent, enlarging annual losses indicate the company remains far from breakeven. Persistent negative profitability erodes investor capital and reduces ability to reinvest in late-stage trials, making sustaining operations dependent on continued external financing over time.
Eroding Equity And Funding DependenceMaterial decline in equity over several years shows capital erosion and less of a balance-sheet buffer. This structural weakening increases the probability of future capital raises, dilutive financings, or constrained strategic choices, limiting long-term investment flexibility.
Isofol Medical AB News
ISOFOL FAQ
What was Isofol Medical AB’s price range in the past 12 months?
Isofol Medical AB lowest stock price was kr0.55 and its highest was kr1.53 in the past 12 months.
What is Isofol Medical AB’s market cap?
Isofol Medical AB’s market cap is kr229.79M.
When is Isofol Medical AB’s upcoming earnings report date?
Isofol Medical AB’s upcoming earnings report date is Aug 25, 2026 which is in 95 days.
How were Isofol Medical AB’s earnings last quarter?
Isofol Medical AB released its earnings results on May 19, 2026. The company reported -kr0.054 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.054.
Is Isofol Medical AB overvalued?
According to Wall Street analysts Isofol Medical AB’s price is currently Overvalued.
Does Isofol Medical AB pay dividends?
Isofol Medical AB does not currently pay dividends.
What is Isofol Medical AB’s EPS estimate?
Isofol Medical AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Isofol Medical AB have?
Isofol Medical AB has 320,491,640 shares outstanding.
What happened to Isofol Medical AB’s price movement after its last earnings report?
Isofol Medical AB reported an EPS of -kr0.054 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -5.636%.
Which hedge fund is a major shareholder of Isofol Medical AB?
Currently, no hedge funds are holding shares in SE:ISOFOL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Isofol Medical AB
Isofol Medical AB (publ), a clinical stage biotech company, develops, commercializes, and sells oncology drugs in Sweden and internationally. The company develops arfolitixorin, which is in phase 3 clinical trial for the treatment of advanced colorectal cancer. It has strategic collaborations with Recipharm, Merck & Cie, and Sahlgrenska University Hospital. The company was incorporated in 2008 and is headquartered in Gothenburg, Sweden.
Technical Analysis
Xintela AB
―
IRLAB Therapeutics AB Class A
―
Modus Therapeutics Holding AB
―
Active Biotech AB
―
Bio-Works Technologies AB
―